Novartis Awaits FDA Action On Aclasta After “Approvable” Letter For Paget’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is waiting to hear back from FDA on the status of zoledronic acid for the treatment of Paget's disease of the bone after responding to an "approvable" letter from the agency